Study on the effect of urinary kallidinogenase after thrombolytic treatment for acute cerebral infarction

被引：4

作者：

Wang, Y. -X. ^{[1
]}

Chen, Y. ^{[1
]}

Zhang, C. -H. ^{[1
]}

Li, C. -H. ^{[1
]}

Dong, Z. ^{[1
]}

Zhao, S. -N. ^{[1
]}

Wang, Z. ^{[1
]}

Zhang, F. -F. ^{[1
]}

Tong, X. -G. ^{[1
]}

Wang, J. -H. ^{[1
]}

Zhang, P. -L. ^{[1
]}

机构：

[1] Tianjin Huanhu Hosp, Dept Neurol, Tianjin Key Lab Cerebral Vasc & Neurodegenerat Di, Tianjin, Peoples R China

来源：

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES | 2015年 / 19卷 / 06期

关键词：

Tissue plasminogen activator; Human urinary kallikrein; Acute cerebral infarction; ISCHEMIC-STROKE; KALLIKREIN; THERAPY; PHASE; TIME;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

OBJECTIVE: To evaluate the safety and efficacy of urinary kallidinogenase for recombinant tissue-type plasminogen activator (rt-PA) intravenous thrombolytic treatment in patients with acute cerebral infarction. PATIENTS AND METHODS: All 200 patients with acute cerebral infarction were randomized 1:1 into an experimental group (100 cases) and a control group (100 cases). Patients in the control groupwere administrated rt-PA (0/9 mg/kg) while patients in the experimental group were given urinary kallidinogenase by intravenous drip (0.15 PNAU/d, for 7 days) after rt-PA intravenous thrombolytic treatment (0.9 mg/kg). The main evaluation index was NIHSS and BI. RESULTS: Compared to the control group, the NIHSS scores were significantly lower 7 and 90 days after thrombolytic therapy (t = 2.391, 2.714; p < 0.05). BI scores were obviously higher at 90 days after thrombolytic therapy in the experimental group (t = 2.675, p < 0.05). CONCLUSIONS: Urinary kallidinogenase may improve the treatment effect for rt-PA intravenous thrombolytic treatment in patients with acute cerebral infraction.

引用

页码：1009 / 1012

页数：4

共 30 条

[1] Arikanoglu A, 2013, EUR REV MED PHARMACO, V17, P1774
[2] Ariturk Z, 2012, EUR REV MED PHARMACO, V16, P617
[3] BHOOLA KD, 1992, PHARMACOL REV, V44, P1
[4] Califano F, 2000, Eur Rev Med Pharmacol Sci, V4, P59
[5] Emanueli C, 2004, ARCH MAL COEUR VAISS, V97, P679
[6] Gökhan S, 2013, EUR REV MED PHARMACO, V17, P653
[7] Hafez S, 2015, TRANSL STROKE RES
[8] The Emerging Role of Tissue Plasminogen Activator in the Management of Severe Frostbite
Ibrahim, Amir E.
Goverman, Jeremy
Sarhane, Karim A.
Donofrio, Jill
Walker, T. Gregory
Fagan, Shawn P.
[J]. JOURNAL OF BURN CARE & RESEARCH, 2015, 36 (02) : E62 - E66
[9] Jiang XG, 2014, EUR REV MED PHARMACO, V18, P1315
[10] Jin X, 2015, J NEUROCHEM

← 1 2 3 →